Glioblastoma multiforme WHO grade IV (GB) is the most common and most malignant primary brain tumor in humans characterized by a high proliferative rate, aggressive invasiveness and a very poor prognosis. Despite an extensive research in the field the standard care of treatment, consisting in maximal surgical resection when applicable, together with radio- and chemotherapy, has been unchanged for many years and awaits the development of novel, more targeted and effective therapies.
Our Division is interested in understanding molecular mechanism underlying glioma cell invasion, which is one of the main causes of glioblastoma recurrence that eventually leads to patients´ death. The current project aims at investigating the cross-talk between cells of the tumor microenvironment (TME) and glioma cells in order to identify novel molecular pathways promoting glioma cell invasion. To this aim we optimized an ex vivo invasion assay based on organotypic brain slice culture (Eisemann et al., 2018, BMC Cancer 18:103) which allows manipulation of tumor cells as well as the microenvironment, permitting the investigation of rate limiting factors of cell migration in a reliable context. The candidate will apply gain-of-function and loss-of-function approaches to define the role of candidate genes in tumor cell migration and invasion using state-of-the-art transgenic and CRISPR/gRNA knock-out technologies in glioma cell lines and tumor neurospheres inoculated into murine organotypic brain slices. These in vitro approaches will be complemented by in vivo studies based on orthotopic implantation of syngeneic glioma cell lines in mice. These cells newly generated in our laboratory, which we recently used to investigate the role of the transmembrane glycoprotein Podoplanin in glioma progression (Eisemann et al., 2018, Neuro Oncol) constitute a highly valuable tool to study not only glioma cell invasion but different aspects of glioma cell biology.
The candidate will characterize the different newly syngeneic glioma cell lines via analysis of RNA and DNA sequencing combined with immunostaining of orthotopic gliomas and employ this preclinical mouse model to study the impact of the tumor microenvironment in brain tumor progression and therapy resistance.
We are looking for a highly motivated and ambitious Postdoc with a Master in the field of biology (or comparable degree) and a Ph.D. to complement our team. The candidate should have a strong background in molecular and cellular biology demonstrated by peer-reviewed publications and a strong interest in brain tumor biology. Excellent experimental and analytical skills in advanced cell culture techniques and mouse genetics including animal experimentation are mandatory. Familiarity with stereotactic device for brain cell implantation and experience with multi-omics datasets are a plus.
- Interesting, versatile workplace
- International, attractive working environment
- Campus with modern state-of-the-art infrastructure
- Salary according to TV-L including social benefits
- Possibility to work part-time
- Flexible working hours
- Comprehensive further training program
- Access to the DKFZ International Postdoc Program
Earliest Possible Start Date: as soon as possible
Duration: The position is limited to 2 years with the possibility of prolongation.
The position can in principle be part-time.
Application Deadline: 19.03.2019
Prof. Dr. Peter Angel
Phone +49 (0)6221/42-4570
Please note that we do not accept applications submitted via email.
The German Cancer Research Center is committed to increase the percentage of female scientists and encourages female applicants to apply. Among candidates of equal aptitude and qualifications, a person with disabilities will be given preference.
To apply for a position please use our online application portal (www.dkfz.de/jobs).
We ask for your understanding that we cannot return application documents that are sent to us by post (Deutsches Krebsforschungszentrum, Personalabteilung, Im Neuenheimer Feld 280, 69120 Heidelberg) and that we do not accept applications submitted via email. We apologize for any inconvenience this may cause.